Rare sublingual sarcoma case expands feline oral tumor differential

A newly published case report in Veterinary Sciences adds an unusual diagnosis to the short list of feline oral tumors: primary sublingual S100-positive undifferentiated pleomorphic sarcoma in a cat. The September 30, 2026 paper describes a 10-year-10-month-old castrated male Korean Shorthair with a progressively enlarging sublingual mass, and the authors frame the case as exceptionally rare in the feline oral cavity. (mdpi.com)

That rarity is what makes the report useful. Oral tumors are a meaningful part of feline oncology, but the overwhelming expectation in practice is still squamous cell carcinoma. Cornell notes that oral cavity cancer is the fourth most commonly diagnosed feline cancer and that SCC accounts for three-fourths or more of oral tumors. More recent retrospective work also supports that pattern: a 2025 Swiss study cited in PubMed and a 2024 Thailand series both identified SCC as the predominant feline oral neoplasm, while mesenchymal tumors made up a smaller, more heterogeneous group. (vet.cornell.edu)

In this case, CT showed a well-circumscribed sublingual mass measuring 2.77 × 3.02 × 1.86 cm, without osteolysis of the mandible or detectable regional lymphadenopathy. That imaging profile matters because bone invasion and nodal spread often shape staging and surgical planning for feline oral tumors. The final diagnosis depended on pathology plus a broad exclusionary immunohistochemistry workup: the neoplastic cells were strongly vimentin-positive and diffusely S100-positive, but negative for pancytokeratin, Melan-A, Iba-1, desmin, and α-SMA. In practical terms, that panel helped rule out epithelial, melanocytic, histiocytic, and muscle-origin tumors before the lesion was classified as UPS. (mdpi.com)

That differential diagnosis is not trivial. Prior feline case reports have shown that oral histiocytic sarcoma can mimic an undifferentiated sarcoma histologically, and older oncology guidance has long warned clinicians to be cautious when a pathology report reads “undifferentiated sarcoma,” particularly in oral sites where amelanotic melanoma can complicate the picture. The S100 positivity here is especially notable because S100 is not specific by itself; in veterinary pathology, it can be seen in melanocytic and some other spindle cell tumors, which is why the negative Melan-A and other exclusionary markers were so important. (pmc.ncbi.nlm.nih.gov)

There doesn’t appear to be much published expert reaction yet to this specific paper, but the broader industry message is consistent. Continuing education and oncology commentary aimed at practitioners emphasize following a structured diagnostic plan for oral masses, obtaining deep incisional biopsies, and using cross-sectional imaging and immunohistochemistry when morphology alone leaves room for error. Recent CE coverage from VMX 2026 similarly stressed systematic workups for oral tumor cases in dogs and cats. (dvm360.com)

Why it matters: For veterinary professionals, this case is less about how often they’ll see sublingual UPS and more about how they approach the next atypical oral mass. When a cat presents with dysphagia, drooling, halitosis, weight loss, or a visible oral lesion, the common diagnoses still deserve priority, but this report reinforces that rare sarcomas belong on the differential list. It also supports a workflow that many referral teams already favor: CT for local extent, biopsy that captures representative deep tissue, and immunohistochemistry broad enough to exclude melanoma, histiocytic sarcoma, and myogenic tumors before settling on a diagnosis of UPS. That can sharpen prognosis conversations with pet parents and reduce the risk of undertreating a locally aggressive lesion based on an incomplete label. (vet.cornell.edu)

The treatment takeaway is narrower but still relevant. In this report, surgical resection was presented as a viable local management option, helped by the absence of bone erosion and detectable nodal disease on CT. Still, one case can’t establish expected outcomes, and the broader feline oral sarcoma literature suggests local behavior can be invasive even when metastatic risk is modest or uncertain. That means margin assessment, follow-up planning, and referral thresholds remain important, especially if future cases show recurrence patterns not captured in a single report. (mdpi.com)

What to watch: The next step for the field is accumulation of comparable cases, ideally with longer follow-up, so clinicians can better understand recurrence risk, metastatic potential, and whether S100-positive feline oral UPS behaves differently from other poorly differentiated oral sarcomas. Until then, this September 30, 2026 report is best read as a diagnostic signal: rare oral sarcomas in cats may require more immunohistochemical workup than a routine oral mass. (mdpi.com)